PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.74%
Negative net income growth while AXSM stands at 62.55%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-40.21%
Negative yoy D&A while AXSM is 11.50%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
147.42%
Some yoy growth while AXSM is negative at -95.86%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-33.50%
Both cut yoy SBC, with AXSM at -49.45%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
2171.95%
Well above AXSM's 370.69% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
577.15%
AP growth well above AXSM's 447.54%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-447.03%
Both reduce yoy usage, with AXSM at -747.11%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-33.50%
Both negative yoy, with AXSM at -640.78%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-13.29%
Both yoy CFO lines are negative, with AXSM at -17.08%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
19.79%
CapEx growth well above AXSM's 6.69%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.79%
Investing outflow well above AXSM's 6.69%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-207.32%
We cut debt repayment yoy while AXSM is 100.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
104.75%
Issuance growth of 104.75% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.